ABSTRACT -The National Institute of Health Sciences (NIHS) and 18 pharmaceutical companies of the Japan Pharmaceutical Manufacturers Association (JPMA) have conducted a validation study intended to evaluate whether a 2-week repeated general toxicity period with histopathological examination is -ing that it is adequate. Evaluation of ovarian toxicity by comprehensive histopathological examination of the female reproductive organs based on the underlying morphology of a normal cycle of the reproductive tract including the ovary and additional immunohistochemical staining with proliferative cell nuclear antigen (PCNA) to identify small follicles may be a good tool to assess female reproductive function. In the collaborative study, 2-or 4-week repeated dose toxicity studies with ovarian histopathological examinations were conducted. A female fertility study was also conducted to compare the results with those of hormone analogues, primordial follicle damaging agents, metabolite imbalance inducers, and endocrine imbalance inducers. Based on the results, ovarian toxicity could be detected by a careful histopatholgi--female fertility parameters (irregular estrous cycle, pre-implantation loss).
INTRODUCTION
At the International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, the Harmonized Tripartite Guideline, "Timing of Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (M3(R1))" reached Step 4 in July 1997 and was amended in November 2000. However, regional differences in the timing of the reproduction toxicity studies to support the inclusion of women of childbearing potential (WOCBP) in clinical trials remain (ICH, 2008) . In Japan, the assessCollaborative work on evaluation of ovarian toxicity by repeated-dose and fertility studies in female rats ment of female fertility and embryo-fetal development must be completed prior to the inclusion of WOCBP using birth control in any type of clinical trial because the current repeated-dose toxicity studies have been considered inadequate for evaluating female reproductive function. On the other hand, the assessment of embryo-fetal development must be completed prior to the Phase I trials in WOCBP and the female fertility studies prior to the Phase III trials in the EU. In the USA, WOCBP may be included in early, carefully monitored clinical studies without reproduction toxicity studies as long as steps are taken to minimize the risk of pregnancy while assessment of female fertility and embryo-fetal development must be completed before WOCBP using birth control are enrolled in Phase III trials. Accordingly, the National Institute of Health Sciences (NIHS) and the Japan Pharmaceutical Manufacturers Association (JPMA) have organized a collaborative study to evaluate whether ovarian toxicities can be detected by repeated-dose general toxicity studies in rats. In the collaborative study, NIHS and 18 pharmaceutical companies of JPMA have now conducted a validation study intended to examine whether a 2-week testing period is adequate to detect the ovarian toxicity of various Mode of action (MOA) chemicals and whether careful histopathological examination of the female reproductive organs would be a good tool to assess female reproductive function. In addition, a female fertility study was also conducted to compare the results with those of the ovarian histopathologi-
The results of the studies conducted by individual companies will be reported by those companies elsewhere. This report is a summary of the assembled data.
MATERIALS AND METHODS
Eighteen JPMA member companies participated in this cooperative investigation and a total of 17 compounds were evaluated. Details of the participating companies, substances used, animal strains, routes of administration and duration of treatment are summarized in Table 1 .
Each company was requested to include the following to the minimum requirements, however, were allowed according to each company's situation. The experimental design of the female fertility study is shown in Fig. 1 . 1) Animal strain: The strains used in this collaborative study were SD, Wistar: Hannover or F344 for the repeated toxicity studies, and SD or Wistar: Hannover for the female fertility studies.
2) Number of animals: At least 10 animals per dose were used in both the repeated toxicity and the fertility studies.
3) Age at treatment initiation: The rats were treated with a test substance until 6 weeks of age for the repeated toxicity studies and until 10 weeks of age for the female fertility study. 4) Test substances: The test substances were selected by the individual participating companies from 4 categories (hormone analogues, primordial follicle damaging agents, metabolite imbalance inducers, and endocrine imbalance inducers) depending on published or in-house data.
5) Dosage selection: The highest dosage of the repeated toxicity and female fertility studies was selected based on the doses that caused any ovarian toxicity in published or in-house data. In principle, the same dosage was selected in both studies. 6) Observations: The clinical signs, estrous cycle and body weight were checked during both studies.
7) Histopathological examination in the repeated toxicity study: After weighing the reproductive and related organs (ovaries and uterus) and representative ones related to the test articles, these tissues and additional ones 10% neutral buffered formaldehyde solution and routinely processed for histopathological analysis. Both ovaries from all the animals were transversely dissected or cut to provide the maximum ovary area for visualization using -hematoxylin and eosin (HE) for the histopathological examination. Immunohistochemistry for proliferating cell nuclear antigen (PCNA) was also performed on serial sections of the ovaries based on the work of Muskhelishvili et al. (2005) . The sections stained with PCNA were main--licles.
8) Terminology used for histopathological analysis --pora lutea formed within one estrous cycle after the most current ovulation, and previous ones formed before the current one estrous cycle. The characteristics of the follicles and corpora lutea at each estrous cycle stage referred to Yoshida et al. (2009) . The terminology and histopathological changes observed in the validation studies were standardized by toxicological pathologists participating in several face-to-face meetings held by JMPA and NIHS. After completion of the examination by each company, a peer review was conducted with Midori Yoshida, Divi- 3, 10, 30 and 300 mg/kg/day for 2 and 4 weeks PO Crl:CD (SD) At histopathological examination, a decrease of ovarian weights at 10 mg/kg and higher in the 4-week study. An increase in large atretic follicles at 10 mg/kg and higher in the 2 and 4 weeks studies at histopathological examination. A decreased uterine weights and/or atrophic findings in the uterus and vagina at 30 mg/kg and 10 mg/kg and hyperplasia in the mammary gland at 3 mg/kg and higher, and 10 mg/kg and higher in the 2 and 4 weeks studies, respectively. Irregular estrous cycles were seen at 3 mg/kg and higher, and 10 mg/kg and higher in the 2 and 4 weeks studies.
Possible by both 2-and 4-week repeated toxicity study Takeda 
PO, SC and IP mean treatment routes by gavage, subcutaneous and intraperitoneal treatments, respectively. 
RESULTS
The summary results of the individual studies are shown in Tables 1 (Repeated toxicity study) and 2 (Female fertility study).
Hormone analogues

Medroxyprogesterone acetate (MPA)
Company: ASKA Pharmaceutical Co., Ltd. Studies: Repeated toxicity and fertility studies Animals; Crl:CD(SD) rats Doses, route and duration: Treatment by gavage at 0, 0.4, 2.0 and 10 mg/kg/day for 2-or 4-week in the repeated toxicity study, and the same doses prior to mating to Day 7 of gestation in the fertility study.
Results: In the general toxicity study, animals with irregular estrous cycle were increased in number and decreased ovary weight was observed at 2.0 mg/kg and greater in the 2-and 4-week-treated groups. On histopathological examination, atretic large follicles were increased and decreased new and old/large or old/small corpora lutea were observed at the same doses in the 2-and 4-week treated groups. In the fertility study, animals with irregular estrous cycle and elongation of mean estrous cycle increased in number at 0.4 mg/kg, which showed no effects on fertility. Decreased number of copulated animals and decreased gestation rate with low preimplantation loss were observed in the 2.0 mg/kg-treated group and no copulation was observed in the 10 mg/kgtreated group.
Conclusion: The changes in fertility induced by MPA were well correlated with histopathological changes of the ovaries after 2 and 4 weeks treatment, which suggests ovarian toxicity of MPA in the general toxicity study.
Reference:
Company: Kissei Pharmaceutical Co., Ltd. Studies: 2 or 4 weeks general toxicity and the fertility studies.
Animals: Crl:CD(SD) rats Doses, route and duration: Treatment by gavage at 0.8, 4, 20 and 100 mg/kg for 2-or 4-weeks in the repeated dose toxicity studies and at 0.8, 4 and 20 mg/kg from 2 weeks before copulation to postcoital day 7 for the female fertility study
Results: In the general toxicity studies, persistent estrus Increased post-implantation loss and dead embryo at 10 mg/kg and higher. Increased body weight and food consumption during pre-mating period at 10 mg/kg and higher.
Reproductive toxicity was detected.
Mitsubishi Tanabe Pharma Corporation
Ishii et al.
PO, SC and IP mean treatment routes by gavage, subcutaneous and intraperitoneal treatments, respectively. as seen in the vaginal smears, multiple cysts in the ovaries at necropsy, increases in luteinized cysts and enlargement of previous formed corpora lutea were observed in histopathological examination of the ovaries in rats receiving 20 mg/kg or more for 2 or 4 weeks. In the female fertility studies, persistent vaginal cornification was also observed at 20 mg/kg and the precoital interval was sig--ly infertile when dosed with 20 mg/kg during the postcoital period. An increase in pre-implantation losses was observed in the animals treated with 20 mg/kg during the pre-coital phase, while treatment with 4 mg/kg mifepristone during the post-coital phase induced an increase in post-implantation losses.
Conclusion: A 2-week administration period would be sufficient to detect the ovarian toxicity of mifepristone in the repeated-dose toxicity study and the pathologthe female reproductive endpoints in the female fertility study.
Reference: Tamura Company: Banyu Pharmaceutical Co., Ltd. Studies: Repeated toxicity and fertility studies Animals: Hanover Crl:WI(HAN) rats Doses, route and duration: Treatment by gavage at 0.005, 0.03, or 0.2 mg/kg/day for 2-or 4-weeks g/kg/day in the repeated toxicity study, and the same doses from prior to mating to Day 7 of gestation in the fertility study.
Results: In the general toxicity and fertility studies, body weight gains associated with decreases in the food consumption, in 2-and 4-week repeated dose toxicity studies and fertility study. In the repeated toxicity study, -es in the large atretic follicles, increases in the interstitial cells and absence of newly formed corpus lutea at 0.2 mg/ kg/day in the 2-week study and at 0.03 and 0.2 mg/kg/ day in the 4-week study. The treatment induced estrogenic and antiestrogenic reactions in the uterus, while mucinous degeneration was detected in the vagina. In female fertility study the effects consisted primary of disturbance of estrus cycle and decreases in numbers of pregnant rats which were considered to be related the ovarian histopathological changes.
topathological evaluation in the repeated toxicity study could anticipate the effects of tamoxifen on female fertility via ovarian dysfunction at slightly toxic doses, and 2-week treatment of tamoxifen at appropriate dose could be -ination.
Reference: Tsujioka et al. (2009) Primordial follicle damaging agents 4-vinylcyclohexene diepoxide (VCD) -1 -ess of apoptosis in small follicles Company: Toa Eiyo Ltd. Studies: Repeated toxicity study Animals: Sprague-Dawley rats (Slc:SD) rats Doses, route and duration: Intraperitoneally treatment at 5, 20 and 80 mg/kg once a day for 2-or 4-weeks in the repeated toxicity study.
Results: In the 2 weeks study, a decrease of small follicles was detected at 80 mg/kg. In the 4 weeks study, the incidence of the decrease was increased at 20 and 80 mg/ kg in histopathological examination with dose-dependent manner.
cient to detect the ovarian toxicity of VCD in histopathological examination of repeated-dose toxicity study at appropriate dose.
Reference: Ito et al. (2009) 
4-vinylcyclohexene diepoxide (VCD) -2 -ess of apoptosis in small follicles
Company: Ajinomoto Co., Inc. Studies: Fertility study Animals: Sprague-Dawley rats (Slc:SD) rats Doses, route and duration: Intraperitoneal treatment at 5, 20 and 80 mg/kg once a day from prior to mating to Day 7 of gestation in the fertility study.
Results: The number and the rate of implantation decreased and the rate of preimplantation loss showed increasing tendency in the 80 mg/kg group. As for the organ weights, decreases in absolute and relative ovary weights were observed in the 80 mg/kg group. In histopathological examination of the ovaries, decrease in the number of small follicles was observed at 80 mg/kg.
Conclusion: Decrease in the number of small follicles was observed at 80 mg/kg in the fertility study.
Reference: Kodama et al. (2009) Animals: Crl: CD(SD) rats Doses, route and duration: Treatment by gavage at 0.1, 0.5, or 1.5 mg/kg/day for 2-or 4-weeks in the repeated toxicity study and the same doses from 2 weeks before mating to day 7 of pregnancy in the fertile study.
Results: In the 2-week general toxicity study, all rats treated with Busulfan showed normal estrous cyclicity and no toxicological changes in the weight and histopathology of the ovaries. In the 4-week study, a decrease in small follicles was observed histopathologically in 1 rat even at 0.5 mg/kg and in 4 rats at 1.5 mg/kg. PCNA immunohistochemistry of the follicles confirmed the above decrease in the number of small follicles at 1.5 mg/ kg. In the female fertility study, increases in dead embryos and post-implantation loss were found in rats at 1.5 mg/kg.
Conclusion: The present study indicates that a 4-week administration period and appropriate assessment, including careful histopathology, of stage-based follicles are needed to detect small follicle depletion in general toxiciReference: Sakurada et al. (2009) Cisplatin drug clinically used as an antitumor agent Company: Toyama Chemical Co., Ltd. Studies: Repeated toxicity and fertility studies Animals: Crl:CD(SD) rats Doses, route and duration: Daily treatment intraperitoneally at dose levels of 0.25, 0.5, 1.0 and 2.0 mg/kg for 2 weeks, or those of 0.125, 0.25 and 0.5 mg/kg for 4 weeks in the repeated toxicity study, and at 0.25, 0.5 and 1.0 mg/ kg from 14 days prior to mating to Day 7 of gestation in the female fertility study.
Results: In the general toxicity study, a decrease in large follicle, an increase in atresia of medium and large follicles, and/or a decrease in currently formed corpus luteum were observed in animals receiving 1.0 and 2.0 mg/kg for 2 weeks, and decreases in small and/or large follicles and an increase in atresia of large follicle were observed in animals receiving 0.25 and 0.5 mg/kg for 4 weeks on the histopathological examination of the ovaries. In the female fertility study, copulation and fertility indices in animals receiving 1.0 mg/kg tended to be lower than that in the control animals.
Conclusion: Histopathological changes attributable to cisplatin dosing were detected by detailed observation of the ovary in the 2-week study, Therefore, it is concluded -uation of ovarian toxicity of cisplatin.
Reference: Nozaki et al. (2009)
Cyclophosphamide
bination cancer chemotherapy regimens Company: Otsuka Pharmaceutical Co., Ltd. Studies: Repeated toxicity and fertility studies Animals: Crl:CD(SD) rats Doses, route and duration: Treatment orally to female rats at dose levels of 0, 5, 10 and 20 mg/kg for the repeated-dose toxicity study for 2-or 4-week, and those of 0, 5, 10, and 20 mg/kg for the female fertility study from 2 weeks prior to mating to Day 7 of pregnancy.
Results: In the repeated-dose toxicity study, increases in large-sized atretic follicles as well as atrophy of corpora lutea were observed in the 20 mg/kg group of 4 weeks study by the histopathological examination of the ovaries. There were no drug-related changes in the ovary of 2 weeks study. In the female fertility study, the number of implantation was slightly decreased and the corpora lutea of pregnancy were not observed in 20 mg/kg group. The dose-dependent increase in incidence of post-implantation loss was observed, and no abnormalities were observed in the estrus cycle and mating in the all treated group.
Conclusion: The histopathological changes in the ovary are important endpoints for evaluation of drugs inducing ovarian damage as well as caesarean section. A 4-week toxicity of CP in the repeated dose toxicity study.
Reference 
Metabolite imbalance inducers Anastrozole
Company: Daiichi-Sankyo Co., Ltd. Studies: Repeated toxicity and fertility studies Animals: CrjDu:F344 female rats for the 2-and 4-week repeated toxicity studies and Crl:CD(SD) rats for the female fertility study. Doses, route and duration: Gavage treatment at 0.01, 0.1, 1 and 50 mg/kg for 2 or 4 weeks in the repeated toxicity study and at levels of 0, 0.01, 0.1, and 5 mg/kg from 2 weeks prior to mating to Day 7 of pregnancy for the female fertility study.
Results: In the general toxicity study, large abnormal atretic follicles, follicular cysts, a decrease in the corpus luteum and depletion of currently formed corpus luteum were observed in the 1 and/or 50 mg/kg groups of both the 2-week and 4-week studies in a histopathological examination of the ovaries. In the female fertility study, the copulation rate and pregnancy rate were decreased in the 5 mg/kg group. Irregular estrous cycles, such as an extended estrous cycle or no estrous cycle, were also observed in the 0.1 and 5 mg/kg groups. At necropsy, decreased numbers of implantations, corpora lutea and live fetuses were noted in the 0.1 and/or 5 mg/kg groups.
Conclusion: Histopathological changes in the ovary are important endpoints for the evaluation of drugs inducing ovarian damage. A 2-week administration period was repeated-dose toxicity study.
Reference: Shirai et al. (2009) 
di(2-Ethylhexyl)adipate (DEHA)
receptors (PPARs) Company: Kowa Company, Ltd. Studies: 2 or 4 weeks general toxicity and fertility studies.
Animals: Crl:CD(SD) rats Doses, route and duration: Treatment by gavage at 200, 1,000 and 2,000 mg/kg for 2-or 4-weeks in the repeated toxicity study and the same doses from 2 weeks before mating until Gestation Days 7 in the female fertility study.
Results: In the general toxicity studies, increase in atresia of large follicle, decrease in currently formed corpus luteum and follicular cyst were observed in the 1,000 mg/kg and above groups. In the fertility study, a significant increase in mean estrus cycle length and postimplantation loss rate were observed in the 1,000 mg/kg -increase in pre-implantation loss rate were observed in the 2,000 mg/kg group. Conclusion: The histopathological changes of ovary observed in the repeated-dose toxicity studies were correlated with the result that DEHA affected the estrus cycle in the female fertility study. A 2-week administration peri--lowing treatment with DEHA by new histopathological examination of the ovaries.
Reference: Wato et al. (2009) 
di-(2-Ethylhexyl) phthalate (DEHP)
receptors (PPARs) Company: Chugai Pharmaceutical Co., Ltd. Studies: 2 or 4 weeks general toxicity and the fertility studies.
Animals: Crl:CD(SD) Doses, route and duration: Treatment by gavage at 300, 1,000 and 3,000 mg/kg in 2-or 4-week in the repeated toxicity study and the same doses from 2 weeks prior to mating to Day 7 of pregnancy in the fertility study.
Results: Histopathology of the ovaries in both repeated-dose toxicity studies showed vacuolation of stromal cells in the groups receiving 300 mg/kg or more and an increased of large atretic follicle in groups at 1,000 mg/ kg or more. In the 4-week study, a decrease in currently formed corpora lutea was observed in the 3,000 mg/ kg group. In the female fertility study, the 3,000 mg/kg group showed prolongation of the mean estrous cycle and irregular estrous cycles. Cesarean section revealed a decrease of pregnancy rate in the 3,000 mg/kg group. No effects on fertility or early embryonic development were found in groups at 1,000 mg/kg or less. Conclusion: Histopathological changes in the ovary are important endpoints for evaluation of drugs which induce ovarian damage. In conclusion, for a repeated-dose toxicity study, a -an toxicity caused by DEHP.
Reference: Takai et al. (2009) Ethylene glycol monomethyl ether (EGME) -gesterone secretion Company: Eisai Co., Ltd. Studies: 2 or 4 weeks general toxicity and the fertility studies.
Animals: Crl:CD(SD) rats Doses, route and duration: Treatment by gavage at 30, 100 or 300 mg/kg for 2-or 4-week in the repeated toxicity study, and the same doses from 2 weeks prior to mating until Day 6 of pregnancy for the fertility study.
Results: In the general toxicity studies, continuous diestrus was seen at 100 mg/kg and higher regardless of the administration periods. The ovarian morphological changes were observed at 100 mg/kg and higher after 2 or 4 weeks of administration characterized by hypertrophy of corpora lutea with decreased cellular debris, which indicated apoptosis, and increased imunohistochemically PCNA negative large atretic follicles. The newly-formed basophilic corpora lutea was scarcely found. In the fertility study, irregular estrous cycles, prolonged mating periods, lower pregnancy rates, and decreased corpora lutea of pregnancy were seen at 100 mg/kg and higher. Irregular estrous cycles observed in some animals at 30 mg/kg were minimal.
Conclusion: The ovarian histopathological changes in the general toxicity studies were well correlated with impaired female fertility found in the fertility study. A general toxicity study with a treatment period for 2 weeks or more is plausible for evaluation of ovarian toxicity induced by EGME.
Reference: Dodo et al. (2009) Indomethacin -ygenase (COX)-1 and -2
Company: Astellas Pharma Inc. Studies: 2 or 4 weeks general toxicity and the fertility studies.
Animals: Crl:CD(SD) rats Doses, route and duration: Treatment by gavage at 0.4, 1.3, or 4 mg/kg for 2-or 4-week in the general toxicity study, and the same doses from 2 weeks before mating until Gestation Days 7 in female fertility study.
Results: In the general toxicity studies, unruptured follicles or luteinized cysts were observed histopathologically in the 4 mg/kg group in both the 2-week and 4-week studies. Follicular cysts were found in the 4 mg/kg group in the 4-week study. Estrous cyclicity was not disturbed in both studies. In the female fertility study, no toxic effects on female fertility parameters were detected in the 0.4 and 1.3 mg/kg group treated with indomethacin, but before completion of the dosing period.
Conclusion: Two weeks of indomethacin treatment is luteinized cyst in the ovary. In addition, 4 weeks of dosing may be required for induction of follicular cysts, although we could not clearly show that these histopathological changes would affect female fertility functions. These present studies suggest that a precise histopathological examination may be able to predict the effect of test articles on female reproductive functions. Reference: Tsubota et al. (2009) 
Compound X
Company: Asahi Kasei Pharma Corporation Studies: 2 or 4 weeks general toxicity and the fertility studies.
Animals: Crl:CD(SD) rats Doses, route and duration: Treatment by gavage at 4, 20, and 100 mg/kg/day for 2-or 4-week in the repeated toxicity study and the same doses from 2 weeks prior to mating to Day 7 of pregnancy in the fertility study.
Results: In the general toxicity study, an increase in atresia of large follicles, a decrease in corpora lutea, granulosa cell exfoliation into antram of large follicles, corpora lutera with retained oocyte, and interstitial gland hyperplasia were observed in all of the treated groups in both the 2-and 4-week studies on histopathological examination of the ovaries. In the female fertility study, the pregnancy rate tended to decrease in the 100 mg/kg/ day group. At necropsy, decreases in the number of corpora lutea, the number of implantations, and the number of live embryos were noted in the 20 and 100 mg/kg/day group. No changes were observed in animals given 4 mg/ kg/day.
logical changes in the ovary are important endpoints for evaluation of drugs inducing ovarian damage. A 2-week -ty of this test compound in the general toxicity study.
Reference : Sato N. et al. (2009) 
Endocrine imbalance inducers Atrazine
Profiles of chemical: A potent herbicide with endocrine-disrupting activity
Company: Nippon Shinyaku Co., Ltd. Studies: 2 or 4 weeks general toxicity and the fertility studies.
Animals: Crl:CD(SD) rats Doses, route and duration: Treatment by gavage at 3, 30 or 300 mg/kg for 2-or 4-week in the repeated dose toxicity study, and at doses of 3, 30 or 100 mg/kg from two weeks before mating to Day 7 of gestation in the female fertility study.
Results: In the two-week repeated-dose toxicity study, prolongation of diestrus and histopathological findings such as loss of the currently formed corpora lutea, decrease in the numbers of previously formed corpora lutea, increase in large-sized atretic follicles, and swelling of the previously formed luteal cells were observed in the 300 mg/kg group, suggesting that atrazine had an anovulatory effect through suppression of the luteinizing hormone surge. In the female fertility study, copulation failure caused by prolongation of diestrus was observed in one animal in the 100 mg/kg group, which could be due to the anovulatory effect of atrazine.
Conclusion: The effect of atrazine on female fertility can be assessed by detailed histopathological examination of ovaries in a two-week repeated-dose toxicity study, provided the appropriate dose levels are selected.
Reference: Shibayama et al. (2009) 
Bromocriptine
Vol. 34 Special Issue I
SP13
Collaborative work to evaluate ovarian toxicity in rats
Company: Sanwa Kagaku Kenkyusho Co., Ltd. Studies: 2 or 4 weeks general toxicity and the fertility studies.
Animals: Crl:CD(SD) Doses, route and duration: Treatment subcutaneously at 0.08, 0.4 and 2 mg/kg for the 2-or 4-week general toxicity study and the same doses from 2 weeks prior to mating to day 7 of gestation in the female fertility study.
Results: Increases of ovarian weights were observed at 2 mg/kg and 0.4 mg/kg and higher in the 2-week and 4-week general studies, respectively. The number of corpora luteum was increased in the 0.4 mg/kg and higher in the 2-and 4-week general toxicity studies by the histopathological examination of the ovaries. bromocriptine did not affect estrous cyclicity in both general toxicity studies. In the female fertility study, although animals in any groups mated successfully, no females in 0.4 and 2 mg/kg groups were pregnant. There were no adverse effects on the reproductive performance in the 0.08 mg/kg group.
Conclusion: The histopathological changes in the ovary are considered important parameters for evaluation of drugs including ovarian damage. A 2-week administration -mocriptine in a general toxicity study.
Reference: Kumazawa et al. (2009) Chlorpromazine hydrochloride (CPZ) Profiles of chemical: A phenothiazine psychoactive antagonistic activity Company: Takeda Pharmaceutical Co., Ltd. Studies: 2-or 4-week general toxicity and the fertility studies.
Animals: Crl:CD(SD) rats Doses, route and duration: Treatment by gavage at dosage levels of 3, 10 and 30 mg/kg/day for 2 and 4 weeks in the repeated-dose toxicity study and the same doses from two weeks before mating to Day 7 of gestation in the female fertility study.
Results: In the general toxicity study, ovarian weights were decreased at 10 mg/kg and higher in the 4-week study and an increase in large atretic follicles was observed histopathologically at 10 mg/kg and higher in the 2 and 4 weeks studies. In addition, decreased uterine -na at 30 mg/kg and 10 mg/kg and higher, mucification in the vaginal epithelium and alveolar hyperplasia in the mammary gland at 3 mg/kg and higher, and 10 mg/kg and higher were seen in the 2 and 4 weeks studies, respectively. Irregular estrous cycles were seen at 3 mg/kg and higher, and 10 mg/kg and higher in the 2 and 4 weeks studies.
The fertility study with dosing from 2 weeks before mating to Day 6 of gestation showed irregular estrous cycles at 10 mg/kg and higher and prolonged copulatory intervals and a reduced fertility index at 30 mg/kg.
Conclusion: Oral CPZ treatment induced ovarian toxicity with 2 weeks or longer treatment and changed the fertility parameters and therefore it was concluded that a 2 weeks administration period is adequate to detect the ovarian toxicity of CPZ.
Reference: Izumi et al. (2009) 
Sulpiride
Company: Mitsubishi Tanabe Pharma Corporation Studies: 2 or 4 weeks general toxicity and the fertility studies.
Animals: Crl:CD(SD) Doses, route and duration: Treatment by gavage at 1, 10, and 100 mg/kg/day for 2-or 4-week in a general toxicity study, and the same doses from the pre-mating period until Days 0-7 of gestation in the fertility study.
Results: In the ovarian histology in the 2-week study, increases in atretic follicle were seen at 1 mg/kg or more and increases in follicular cysts at 10 mg/kg or more. In more, and a decrease in large follicles was seen at 10 mg/ kg or more. Increased body weight gain was observed at 10 mg/kg or more in the 2-and 4-week studies. The females in these groups exhibited the development of mammary alveolus. In the fertility study, sulpiride-treated females showing persistent diestrus resulted in successful mating, and almost females got pregnant. However, increased implantation loss was observed at 10 mg/kg or more, which was considered to be caused by the adverse effect of sulpiride on oocyte development.
Conclusion: Sulpiride-induced ovarian toxicity was seen at 1 mg/kg or more in the 2-and 4-week repeateddose toxicity studies, and the observed ovarian changes were considered to be related to adverse effects on female fertility.
Reference: Ishi et al. (2009) Comparison of the results among the fertility, and repeated toxicity studies The comparison of endpoints of ovarian toxicities and their lowest toxicity doses among the fertility, 2-week or 4-week toxicity studies is shown in Table 3 . All compounds induced ovarian toxicity, and they were detectable in both the general toxicity and fertility studies. In the general toxicity studies, only 2 compounds, busul- Table 3 . Comparison of NOAEL and ovarian toxicities observed in female fertility and general toxicity studies. in the ovary in 2-week toxicity study. They are alkylating agents, and categorized into small follicle damaging chemicals. Their lowest toxicity doses of 6 compounds in the general toxicity studies were lower than those in their fertility studies. Their lowest toxicity doses of 7 compounds in the fertility study were lower than those in their general toxicity studies. Their lowest toxicity doses of the remaining 4 compounds in the general toxicity studies were the same as those in fertility studies.
Histopathological terms in the ovary observed in the present validation study the present collaborative work are shown in Table 4 . The follicles, and appeared in all categorized studies. Follicular cyst was observed in several categories. Decreases or depletion of corpus lutem formed in the current or previ--lar cysts also wee found in 2 categorized areas. Decreases of small follicles were only observed in the compounds damaging small follicles. Histopathological changes related with non-ovulated follicles including unruptured follicle, unruptured luteinized follicle, luteinized cyst/luteal cyst, expansion of cumulus oophorus were observed in the compounds categorized into hormonal analogues and metabolite imbalance inducers.
DISCUSSION
This is a summary of the collaborative work organized by NIHS and JPMA to evaluate whether ovarian toxicities are detected by repeated-dose general toxicity studies in rats. Eighteen pharmaceutical companies that participated in the collaborative study and examined whether a 2-week testing period is adequate to detect ovarian toxicity. In this study, 2-or 4-week repeated-dose toxicity studies with ovarian histopathological examinations were conducted using 17 compounds which have been reported to be or were expected to be ovarian toxicants. These compounds were categorized into hormone analogues, primordial follicle damaging agents, metabolism imbalance inducers, and endocrine imbalance inducers. In order to compare the results with those of the ovarian hisfertility study was also conducted. In the present validation study, a common study design was applied, and careful histopathological examination of the female reproductive tract based on ovarian physiology , PCNA immunohistochemical staining for detection of small follicles (Muskhelishvili et al., 2005) and continuous observations of estrous cyclicity were added to the general toxicity study. The highest dosages of the general toxicity and female fertility studies were selected from the doses that demonstrated ovarian toxicity in published or in-house data. In principle, the same dosage was selected in both studies. Four weeks are considered to be the appropriate period to detect any ovarian toxicity in rats because approximately 27 days is accepted to be a period of follicular development from medium follicles and Peters (1968)) (Greenwald and Roy, 1994) .
The present validation study demonstrated that all the compounds investigated induced ovarian toxicity in both general toxicity and fertility studies except lack of reprotoxicity of indomethacin. This result suggests that any of the parameters for the ovary in the general toxicity -teen compounds affected the ovary in both 2-and 4-week treatment studies, 2 alkylating agents categorized as small follicle damaging chemicals, busulfan and cyclophosphamide, did not induce noteworthy changes in the ovary. However, ovarian toxicities were detected from these 2 compounds in the 4-week treatment. Their dose selections were considered to be appropriate for a 2-week study because typical general toxicities were observed with them. The 2-week treatment with the other 2 compounds detect damage to small follicles using the present study design. Since both busulfan and cyclophosphamide are cytotoxic agents, other data such as the pharmacological action of the compounds investigated might be more informative for the prediction of ovarian toxicity.
A comparison of lowest toxicity doses in the ovary between the general toxicity and female fertility studies category based on MOA category in the present validation study. The doses for the ovarian toxicity in the general toxicity studies were the same or lower than those in the female fertility study in 10 out of 17 chemicals, suggesting that a general toxicity study might be less sensitive for the detection of the female reproductive toxicity. If any chemical had effects on the ovary in the general toxicity study, the female fertility might be affected at lower levels.
The histopathological changes observed in the present validation study demonstrated useful indicators for the -ings were increases in large-sized atretic follicles and decreases in the corpus luteum. They indicate that the treatment resulted in a disturbance of ovulation and large follicle development, although MOA was different among the chemicals. The lasting disturbances will lead to atro--ation involving large sized follicular atresia. Decreases in the small follicles were only observed with the compounds that damaged small follicles, VCD, cisplatin and busulfan. This result indicates that a qualitative histopathological examination using single transverse sections might be suitable for screening of detecting damage to small follicles. Our results also support a position paper published by The Society of Toxicologic Pathology (STP) ovary evaluation working group on histopathological approaches for the assessment of rodent reproductive toxicity. This paper recommended qualitative evaluation of the ovary as et al., 2005) . In addition, -small follicles (Muskhelishvili et al., 2005) . If effects on the small follicles are predicted in the qualitative analysis, a further approach including MOA should be performed. Our validation study also provided very informative evidence that the chemicals related to non-ovulated follicles induced common histopathological changes such as unruptured follicles, unruptured luteinized follicles, luteinized/luteal cysts, expansion of the cumulus oophorus, and cystic corpus lutea Tsubota et al., 2009) . When the estrous cycle is normal and no degenerated oocytes are found, distinguishing the corpus luteum with a cavity from a cystic corpus luteum or a luteinized cyst after normal ovulation, More information on these lesions is required. In the fertility study, all the compounds except for indomethacin reflected alterations in the female fertility parameters, such as an irregular estrous cycle and increased pre-implantation loss. As for the irregular estrous cycle, it might be correlated with the disruption of ovulation, increases in atresia of the follicles and decreases in newly formed corpus lutea and so on. The hormonal alterations induced by the hormone analogues may directly affect the estrous cycle. In the metabolic imbalance inducers, prolongation of the estrous cycle and decrease in pregnancy rate were observed. The preimplantation loss described by the primordial follicle damaging agents VCD, cisplatin, busulfan and cyclophosphamide, was considered to be a consequence of decrease in the number of small follicles. In the case of endocrine imbalance inducers, bromocriptine induced a blockade of prolactin surges and subsequent reduction in progesterone secretion resulting in persistent of the corpus lutea and disturbance of implantation. Another endocrine imbalance inducer, chlorpromazine, suppressed ovulation and induced atresia of the follicles, resulting in a decrease in the implantachanges observed in the ovaries in the repeated-dose tox--ductive parameters.
In conclusion, ovarian toxicity could be detected by careful histopatholgical examination. A 2-week dosing -icity, except for cytotoxic compounds such as alkylat-
